NZ225924A

NZ225924A - 2-substituted phenyl -4-quinoline carboxylic acid derivatives and pharmaceutical compositions containing such

Info

Publication number: NZ225924A
Application number: NZ225924A
Authority: NZ
Inventors: Leslie H Sutherland; Adolph E Sloboda; Ralph Grassing Child; John F Poletto; Dennis W Powell
Original assignee: American Cyanamid Co
Priority date: 1987-08-31
Filing date: 1988-08-24
Publication date: 1991-07-26
Also published as: AU2167888A; NO174961C; PL156232B1; US4847381A; ZA886443B; EP0305952B1; NO174961B; KR970005909B1; DD282225A5; PH26258A; FI883997A; IL87457A0; ES2058191T3; CS587588A2; CA1333606C; NO883865L; KR890003703A; PT88365A; NO883865D0; JPH01110673A

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £25924 & % \ f e o Priority Oate(s): 3i )..'SO NEW ZEALAND PATENTS ACT, 1953 22 5 9 2 4 Complete Specification Filed: Class: (5) : Publication Date: . 2.A.JIIJL..DM t-.0. Journal, No: o No.: Date: COMPLETE SPECIFICATION SUBSTITUTED 2-PHENYI-4-QUIN0LINE CARBOXYLIC ACIDS O 1*7We, AMERICAN CYANAMID COMPANY, a corporation organized and existing under the laws of the State of Maine, United States of America, and having its executive offices at Wayne, New Jersey, United States of America, hereby declare the invention for which I-/ we pray that a patent may be granted to me-/us, and the method by which it is to be performed, to be particularly described in and by the following statement: - - 1 (followed by page la) 225924 -la - Title: SUBSTITUTED 2-PHENYL-4-OUINOLINE CARBOXYLIC ACIDS BRIEF SUMMARY OF THE INVENTION This invention is concerned with compounds of the formula: N.Z. PATENT Of FICE 19 APR 1991 MCttVIP (i) wherein R1 is hydrogen, halogen or alkylfC^-C^); R2 is hydrogen, halogen, trifluoromethyl or alkyl(C^-C^); R3 is hydroxy or alkanoyloxy(C2~C6); R4 is halogen, hydroxy, alkyl (Cj^-Cg) , trif luoromethyl, cycloalkyl (Cg-Cg), phenyl, benzyl, phenoxy, phenylthio, 2,4-dichlorophenoxy or mono-or di-substituted phenyl wherein the substituents are halogen or alkoxy(C1~C3); and R5 is hydrogen or halogen; with the proviso that when Rj is hydrogen, R2 is other than fluoro, and R3 is hydroxy then R4 may not be chloro, bromo, iodo, methyl or phenyl. 225924 - 2 - In addition this invention is also concerned with pharmaceutical compositions comprising a compound of the formula(I) in association with a pharmacologically acceptable carrier. DETAILED DESCRIPTION OF THE INVENTION j^q The compounds of formula (I) may be readily prepared in accordance with the following reaction scheme: a) 60 15 ■*60 wherein R, R. and Rg are as hereinbefore defined and With reference to 1' 2' "4 2q Rg is -C2H5 or -CH2OCO-alkyl (Cj^-Cg) the above reaction scheme, an appropriately substituted 2,3-indolinedione (1) in aqueous solution made basic with an alkali metal hydroxide and warmed, is mixed with a (C1-C2) alkanolic solution of an appropriately substituted 25 acetophenone (2), and the resulting reaction mixture is held at the reflux temperature for several hours. During this process, a portion of the (Cx-C2) alkanol is removed by distillation, the residue is heated further at reflux, then cooled and filtered and the filtrate acidified 30 where-upon the desired product (I) precipitates. The product (I) is then collected by filtration and, if necessary, recrystallized by conventional procedures. The compounds of the present invention are active immunosuppressive agents when administered to 35 warm-blooded animals. As such they are effective in treating conditions where elevated levels of antibody 225924 -3- production or monocyte/lymphocyte activity as a result of the hyperreactivity of the immunoregulatory network are closely associated with the development of autoimmune diseases, including rheumatoid arthritis [Mellbye, 0. J. and Natvig, J. B., Clin. Exp. Immunol., £, 889 (1971)], multiple sclerosis [Tourtellotte, w. w. and Parker, J. A., Science 154. 1044 (1966)], systemic lupus erythematosis [Abdu, N. I., et ai., Clin. Immunol. Immunopath., £, 192 (1976)], thyroiditis [Witebsky, E., et al., J. Immunol., 103. 708 (1969)], mixed connective tissue disease [Sharp, G. C., gt ai., Am. J. Med., 51, 148 (1972)], dermato/polymyositis [Venables, P. J. W., et al., Ann. Rheum. Dis., £0, 217 (1981)], insulin-dependent diabetes [Charles, M. A., £t al-, J. Immunol., 130, 1189 (1983)] and in patients undergoing organ transplantation. The immunosuppressive activity of the compounds of this invention was established in the following test. Acute Graft-vs.-Host Reaction An acute graft-vs.-host (GvH) reaction was induced in normal B6D2F1 male mice by the intravenous injection of 30-50 x 106 parental spleen cells of the C57BL/6 parent. Ten days post GvH induction the B6D2F1 mice were acutely immunosuppressed. On day 10, spleen cells from the B6D2F1 mice were removed asceptically, placed in tissue culture and stimulated with T-cell mitogen [Concanavalin-A (Con-A) ] at a concentration of 2 pg/inl. The ability of the spleen cells to proliferate in response to the mitogen was determined by pulse labeling of divid- 3 ing cells with H-thymidine for the last 24 hours of the 72 hour tissue culture period. The labeled cells were 3 harvested on millipore filters and the amount of H radioactivity was quantitated with a liquid scintillation spectrometer. Drug dosing began on the day of GvH induction and continued through the 10 day in vivo protocol. The test compounds were administered orally in a phosphate buffer pH 7.4 vehicle containing 0.025M phosphate, 0.075M sodium chloride and 0.002% polysorbate 20. The data from -4 22 5 9 2 4 drug dosed mice was compared with GvH mice dosed with vehicle and with normal mice. A compound is considered active if it reduced the degree of suppression seen in the Con-A proliferative response of vehicle treated GvH mice compared with normal mice. The results of this test on representative compounds of this invention appear in Table I. TABLE I Graft-vs.-Host Reaction Con-A Dose Response Percent 3 Compound (mg/kg) GvH H cpm Suppression None - - 120386 Vehicle - + 32428 73 2-(4-Chlorophenyl)-3- 50 + 96487 20 hydroxy-6-iodo-4-quino- linecarboxylie acid None - - 295315 Vehicle - + 169220 43 2-(1,1'-Biphenyl]—4—yl— 50 + 278001 6 6-bromo-3-hydroxy-4- quinolinecarboxylic acid None - - 181886 Vehicle - + 17161 91 3-(Acetyloxy)-2-[l,1'- 50 + 128187 29 biphenyl]-4-yl-4-quinolinecarboxylic acid None - - 295315 Vehicle - + 169220 43 3-Hydroxy-6-methyl-2- 50 + 285448 3 [1,1*-biphenyl]-4-yl-4- quinolinecarboxylic acid o J ■w 10 15 20 25 30 35 22 5 9 2 4 -5- TABLE I (continued! Dose Con-A Response Percent Compound (mg/kg) GvH H cpm Suppression None Vehicle 6-Fluoro-3-hydroxy-2-[1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid 50 + + 157509 74145 139289 53 12 None Vehicle 2-(4-Chlorophenyl)-6-fluoro-3-hydroxy-4-quinolinecarboxylic acid 25 248699 + 28206 + 183441 89 26 None Vehicle 6-Fluoro-2-(2•-fluoro-(1,1*-biphenyl]-4-yl)-3-hydroxy-4-quinolinecarboxyl ic acid 50 157509 + 74145 + 129464 53 18 In addition these compounds are effective in treating inflammation and joint destruction associated with arthritic disease in warm-blooded animals as established in the following test. Induction of Adjuvant Arthritis Outbred, male, Royalhart Wistar rats (Royalhart Farms, New Hampton, NY), weighing approximately 165 g, were injected intradermally in the right hind paw with killed and dried Mycobacterium tuberculosis emulsified in mineral oil (adjuvant) at a dose of 2 mg/kg of body weight. This protocol for induction of arthritis has been described in detail by A. E. Sloboda and A. C. Osterberg, Inflammation, 1, 415 (1976). -6- 22 5 9 2 4 Seven days subsequent to immunization with the adjuvant, the rats were divided into groups and treated daily by gavage with various doses of the test compounds. Control groups of rats were immunized with adjuvant, but 5 then treated only with starch vehicle. At the end of 23 days post adjuvant immunization, the left hind paw diameters of all the rats were measured around the ankle joint with a vernier caliper. The results of this test on representative com-10 pounds of this invention are shown in Table II. The statistical significance of differences between control and treated group were calculated using Students t test. TAPES IX Treatment of Adjuvant Induced Arthritis Compound Daily Number Dose of mg/kg Animals Final Rat Wt. (gm) Arthritic Paw Diameter (mm) 20 Arthritic Controls (pooled) - 446 244 11.8 25 2-(4-Chlorophenyl)-3-hydroxy-6-iodo-4-quino-1inecarboxylic acid 50 15 276 9.0* 6-Chloro-2-(4-chloro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 8 275 7.5* 30 2-[1,1•-Biphenyl]-4 -y 1- 3-hydroxy-4-quinolinecarboxyl ic acid 12.5 15 303 7.8* 35 2-(4-Chlorophenyl)-3-hydroxy-4-quinolinecarboxyl ic acid 50 17 291 9.0* 2-[1,1'-Biphenyl]-4-yl- 12.5 17 267 8.6* 6-bromo-3-hydroxy-4- quinolinecarboxylic acid -7- 22 5 9 2 4 TABLE II (continued! Treatment of Adjuvant Induced Arthritis Compound Daily Number Dose of mg/kg Animals Final Rat Wt. (gm) Arthritic Paw Diameter (nun) 2-(4-Bromophenyl)-3-hydroxy-6-iodo-4-quino-1inecarboxylic acid 25 11 244 9.9* 3-Hydroxy-2-(4-iodo-phenyl)-4-quinolinecarboxyl ic acid 50 15 314 9.3* 3-(Acetyloxy)-2-[1,1'-biphenyl]-4-yl-4-quino-1inecarboxylic acid 12.5 14 319 7.7* 3-Hydroxy-6-methyl-2-[1,1'-biphenyl]-4-yl-4-quinolinecarboxy1ic acid 12.5 17 317 8.4* 6,8-Dichloro-3-hydroxy-2—[1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid 12.5 13 301 8.4* 3-Hydroxy-8-methyl-2-[1,1*-biphenyl]-4-yl-4-quinolinecarboxylic acid 50 12 291 7.6* 6-Fluoro-3-hydroxy-2-[1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid 3.13 8 284 9.68* 2-(3,4-Dichlorophenyl)- 3-hydroxy-6-methyl-4-quinolinecarboxylic acid 50 14 269 9.2* 2-(4-Chlorophenyl)-6-f1uoro-3-hydroxy-4-quinolinecarboxylic acid 25 13 276 8.1* -8- TABLE II (continued! 22 5 9 2 4 Compound Daily Number Dose of mg/kg Animals Final Rat Wt. (gm) Arthritic Paw Diameter (mm) 3-(Acetyloxy)-2-[1,1' -biphenyl]-4-yl-6-bromo--4-quinolinecarboxylic acid 6.25 17 325 9.0* 6-Fluoro-2-(21-fluoro-(1,1'-biphenyl]-4-yl)-3-hydroxy-4-quinolinecarboxyl ic acid 6.25 17 273 8.1* 6-Bromo-2-(4-chloro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 14 295 8.1* 6,8-Dichloro-2-(4-chlorophenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 12 271 8.4* 2-(4-Chlorophenyl)-3-hydroxy-6-methyl-4-quinolinecarboxylic acid 50 14 275 9.0* 6-Bromo-3-hydroxy-2-(4-iodophenyl)-4-quinoline-carboxylic acid 50 14 322 8.7* 6-Fluoro-2-(4-fluoro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 25 17 273 10. 5* 6-Bromo-3-hydroxy-2-(4'-methoxy[1,1'-biphenyl]-4-yl)-4-quinolinecar-boxylic acid 50 17 290 8.3* -9- 22 5 9 2 4 TABLE II (continued! Compound Daily Dose mg/kg Number of Animals Final Rat Wt. (gm) Arthritic Paw Diameter (mm) 6-Bromo-2-(4-fluoro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 12 271 9.0* 2-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-4-quinolinecarboxylic acid 50 14 300 8.2* 6-Bromo-2-(2,4-difluoro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 15 270 8.9* 6-Chloro-3-hydroxy-2-(4 • -methoxy [ 1,1 • -biphenyl ]-4-y1)-4-quino-linecarboxylic acid 50 15 269 7.3* 6-Fluoro-3-hydroxy-2-(4'-methoxy[1,1•-biphenyl ]-4-yl)-4-quino-1inecarboxylic acid 25 17 286 8.4* 6,8-Dichloro—2-( 3,4-di-chlorophenyl)-3-hydroxy-4-quinolinecarboxylic acid 25 7 298 8.1* 6,8—Dichloro—3-hydroxy— 2-(4-iodophenyl)-4-quinolinecarboxylic acid 50 12 276 8.6* ♦Statistically significant suppression of arthritic paw diameter relative to the arthritic controls, p = <.05 by students t test. - 10 - 22 5 9 2 4 The inhibition of progressive joint deterioration was demonstrated by the following test. Inhibition of Progressive Joint Destruction This protocol is identical to the experiment whose results were described in Table I. At the end of 23 days the rats were killed, their left hind paws amputated and radiographic evaluation was made as follows: Joint roentgraphs of the left hind paws were prepared on Polaroid x-ray film (type 55) using a Faxitron x-ray unit (Model 43805-N, Hewlett Packard, McMinnville, OR). The focus to film distance was 45cm and the exposure to the x-ray source was 5 minutes at 60KVP. Each radiograph was graded (blind) for the presence and severity of the following parameters: a) juxtaarticular erosions of the tarsal bones; and b) cartilage space narrowing. A grade of 0 to 4 (with = normal and 4 = severe changes) was assigned to each of the parameters. Again the statistical significance between arthritic controls and treated rats were determined by the use of Students t test. The results of this test on representative compounds of this invention are shown in Table III. mriiamM'iiMii.iiMiHifilirii'Hnunmi ninwr 22 5 9 2 A TABLE III Inhibition of Induced Joint Deterioration X-Ray Scores Daily Dose No. of Cartilage Compound mg/kg Animals Erosions Space Arthritic Controls - 9,668 3.12 3.27 (historical) 2-(4-Chlorophenyl)-3- 50 15 1.86* 2.29* hydroxy-6-iodo-4-quino-1inecarboxylic acid 6-Chloro-2-(4-chloro- 50 8 1.17* 1.67* phenyl)-3-hydroxy-4-quinolinecarboxylic acid 2-(1,1*-Biphenyl)-4-yl- 12.5 15 2.07* 1.67* 3-hydroxy-4-quinolinecarboxyl ic acid 2-(4-Chlorophenyl)-3- 50 17 1.53* 1.94* hydroxy-4-quinolinecarboxyl ic acid 2-[1,1'-Biphenyl]-4-yl- 12.5 17 1.64* 2.16* 6-bromo-3-hydroxy-4-quinolinecarboxylic acid 3-Hydroxy-2-(4-iodo- 50 15 1.57* 2.00* phenyl)-4-quinolinecarboxylic acid 3-(Acetyloxy)-2-[1,11- 12.5 14 1.64* 1.64* biphenyl]-4-yl-4-quino-1inecarboxylic acid 22 5 9 2 4 TABLE III (continued! X-Ray Scores Daily Dose No. of Cartilage Compound mg/kg Animals Erosions Space 3-Hydroxy-6-methyl-2- 12, [1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid .5 17 2 .03* 1 .97* 6,8-Dichloro-3-hydroxy- 12. 2-[1,1•-biphenyl]-4-yl-4-quinolinecarboxylic acid .5 13 2 .46* 2 .38* 3-Hydroxy-8-methyl-2- 50 [1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid 12 1. .95* 2. .32* 6-Fluoro-3-hydroxy-2- 3. [1,1'-biphenyl]-4-yl-4-quinolinecarboxylic acid 13 16 1. ,94* 2. .13* 2-(3,4-Dichlorophenyl)- 50 3-hydroxy-6-methyl-4-quinolinecarboxylic acid 14 2. 29* 2. 21* 2-(4-Chlorophenyl)-6- 25 fluoro-3-hydroxy-4-quinolinecarboxylic acid 13 1. 21* 1. 42* 3-(Acetyloxy)-2-[1,1*- 6.25 17 1.71* 2.06* biphenyl]-4-yl-6-bromo--4-quinolinecarboxylic acid - 13 - 225924 TABLE III (continued) X-Ray Scores Daily Dose No. of Cartilage Compound mg/kg Animals Erosions Space 6-Fluoro-2-(2'-fluoro- 6.25 17 2.53* 1.53* {1,1'-biphenyl]-4-yl)-3-hydroxy-4-quinoline-carboxylic acid 6-Bromo-2-(4-chloro- 50 14 2.19* 1.69* phenyl)-3-hydroxy-4-quinolinecarboxylic acid 6,8-Dichloro-2-(4- 50 12 2.17* 1.75* chlorophenyl)-3-hydroxy-4-quinolinecarboxyl ic acid 2-(4-Chlorophenyl)-3— 50 14 2.07* 1.43* hydroxy-6-methyl-4-quinolinecarboxylic acid 6-Bromo-3-hydroxy-2- 50 14 2.07* 1.86* (4-iodophenyl)-4- quinolinecarboxylic acid 6-Fluoro-2-(4-fluoro- 25 17 2.6* 2.8 phenyl)-3-hydroxy-4-quinolinecarboxylic acid 6-Bromo-3-hydroxy-2- 50 17 1.65* 1.59* (4'-methoxy(1,1'-biphenyl] -4-yl) -4-quino-1inecarboxylic acid 4 i 7i O o - 14 -TABLE III (continued! 22 5 9 2 4 Compound X-Ray Scores Daily Dose No. of Cartilage mg/kg Animals Erosions Space 6-Bromo-2-(4-fluoro-phenyl)-3-hydroxy-4-quinolinecarboxylic acid 50 12 2.17* 2-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-4-quinolinecarboxylic acid 50 14 2.5* 6-Bromo-2-(2,4-di-fluorophenyl)-3-hy-droxy-4-quinolinecarboxylic acid 50 15 1.0* 6-Chloro-3-hydroxy-2-(4'-methoxy[1,1•-biphenyl] -4-yl)-4-quino-1inecarboxylic acid 50 15 1.67* 6-Fluoro-3-hydroxy-2-(4'-methoxy[1,1'-biphenyl] -4-yl)-4-quino-1inecarboxylic acid 25 17 2.22* 2.42* 1.79* 1.67* 0.60* 0.89* ♦Statistically significant suppression of arthritic paw diameter relative to the arthritic controls, p = <.05 by students t test. - 15 - 22 5 9 2 4 The compounds of this invention may be orally administered to treat arthritis, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or 5 they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the 10 like. Such compositions and preparations should contain at least 0.1% of the active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active com-15 pound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions according to this invention are prepared so that an oral dosage unit contains between about 50 and 250 mg of active compound. The tablets, capsules and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When the dosage unit form is a capsule it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. These active compounds may also be administered parenterally. Solutions or suspensions of these active 20 25 30 35 t f, "1 *'# 4 • 225924 - 16 - compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary con-5 ditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of f~\ sterile injectable solutions or dispersions. In all cas- es, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microor- 15 ganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. 2q The invention will be described in greater de tail in conjunction with the following specific examples. Example 1 2 - (4-Chiorophenvl) -3-hvdroxv-6-iodo-4-cruinol inecarboxyl ic acid 25 This compound was prepared by the method of Mar shall and Blanchard, J. Pharmacol. Exp. Ther., 9J5, 185 (1949), mp 199.5-200°C. j The compounds of Examples 2-12, named below, 30 35 were made by the same procedure. Example Name MP°C 2 6-Chloro-2-(4-chlorophenyl)- 212-214 3-hydroxy-4-quinolinecarbox- ylic acid 3 2-[1,1'-Biphenyl]-4-yl-3- 196-201 hydroxy-4-quinolinecarboxylic acid - 17 - 22 5 9 2 4 Example Name m.p.°C. 4 2-(4-Chlorophenyl)-3-hy- 211-212 droxy-4-quinolinecarboxylic acid 5 2 - [ 1,11-Biphenyl]-4-yl—6— 225 bromo-3-hydroxy-4-quinolinecarboxyl ic acid 6 3-Hydroxy-6-methyl-2-(4- 155-157 methylphenyl)-4-quinolinecarboxylic acid 7 2-(4-Bromophenyl)-3-hydroxy- 214.5-215.5 6-iodo-4-quinolinecarboxylic acid 8 2-(4-Bromophenyl)-3-hydroxy- 248-249 4-quinolinecarboxylic acid 9 3-Hydroxy-6-iodo-2-(4-iodo- 228-230 phenyl)-4-quinolinecarbox- ylic acid 10 6-Bromo-2-(4-bromophenyl)-3- 216-217 hydroxy-4-quinolinecarboxylic acid 11 6,8-Dibromo-2-(4-bromophen- 212-213 yl)-3-hydroxy-4-quinolinecarboxylic acid 12 3-Hydroxy-2-(4-iodophenyl)- 253-255 4-quinolinecarboxylic acid Example 13 3-(Acetyloxv)-2-f1.1'-biphenvl1-4-vl-4-ouinolinecarboxyl ic acid A 10.4 g portion of 2-[1,1'-biphenyl]-4-yl-3-hy-droxy-4-quinolinecarboxylic acid was treated with 50 ml of acetic anhydride and 20 drops of concentrated sulfuric acid. The mixture was heated for 1/2 hour on a steam bath with occasional swirling, then poured into 300 ml of ice water, stirred and treated with sodium bicarbonate solution until weakly acid. The solid was collected, washed with water, dried and recrystallized from 400 ml of ethanol, giving 6.0 g of the desired product as yellow-orange crystals, mp 199-200°C. 25 30 - 18 - 22 5 9 2 4 Example 14 2-f1.11-biphenvl1-4-vl-6-fluoro-3-r(1-oxohexvl1oxv1--4-ouinolinecarboxylic acid A suspension of 3.59 g. of 6-fluoro-3-hydroxy-2-5 (1,1 • -biphenyl) -4—quinol inecarboxylic acid in 17 mL of hexanoic anhydride was treated with 6 drops of sulfuric acid. The mixture was stirred (over-head) and heated at 100°C. (steam-bath) for 3 hours. The reaction mixture was cooled and poured over 100 g. of ice. The aqueous ^ 10 suspension was neutralized to pH=7 with 5N NaOH. After stirring for 15 min., the ester was extracted from the aqueous phase with ethyl acetate (200 mL). The organic extract was washed with brine, dried over magnesium sulfate, filtered and then concentrated to approximately 15 25 mL. The resulting crystalline solid was collected, washed with cold ethylacetate and air-dried to afford 2.2 g of the desired product, m.p. 179-206°C. Example 15 2-f1.1'-biphenvll-4-vl-6-fluoro-3-r d-oxopentvlloxvl-20 -4-cruinolinecarboxylic acid A suspension of 3.59 g. of 6-fluoro-3-hydroxy-2-(1,1* -biphenyl) -4—quinol inecarboxylic acid in 17 mL of valeric anhydride was treated with 6 drops of sulfuric acid. The mixture was stirred (over-head) and heated at q 100 C. (steam-bath) for 3 hours. The reaction mixture was cooled and poured over 100 g of ice. The aqueous suspension was neutralized to pH=7 with 5N NaOH. After stirring for 15 min., the ester was extracted from the aqueous phase with ethyl acetate (200 mL). The organic extract was washed with brine, dried over magnesium sulfate, filtered and then concentrated to approximately 25 mL. The resulting crystalline solid was collected, washed with cold ethylacetate and air-dried to afford 3.0 g. of the desired product, m.p. 214-217°C. 35 •225924 . 1 - 19 - •<' V. •4 4 Example 16 2-fl. 1 '-biphenvn-4-vl-3-f2 .2-dimethvl-l-oxopropoxv) -6-fluoro—4-ouinolinecarboxvlic acid | A suspension of 3.59 g. of 6-fluoro-3-hydroxy-2- 5 (l,l'-biphenyl)-4—quinolinecarboxylic acid in 17 mL of trimethylacetic anhydride was treated with 6 drops of sulfuric acid. The mixture was stirred (over-head) and heated at 100°C. (steam-bath) for 3 hours. The reaction mixture was cooled and poured over 100 g. of ice. The ,aqueous suspension was neutralized to pH=7 with 5N NaOH. v After stirring for 15 min., the ester was extracted from the aqueous phase with ethylacetate (200 mL). The organic extract was washed with brine, dried over magnesium sulfate, filtered and then concentrated to approximately ^5 15 mL. The resulting crystalline solid was collected washed with cold ethylacetate and air-dried to afford 2.8 g of the desired product, m.p. 215-217°C. Example 17 2-n.1'-biohenvll-4-vl-3-(2-methvl-l-oxopropoxv)-6-fluoro -4-quinolinecarboxvlic acid A suspension of 2.5 g. of 6-fluoro3-hydroxy-2-(l,l•-biphenyl)-4—quinolinecarboxylic acid in 20 mL of isobutyric anhydride was treated with 6 drops of sulfuric acid. The mixture was stirred 20 O 25 35 (over-head) and heated at 100°C. (steam-bath) for 3 J hours. The reaction mixture was cooled and poured over ! 100 g. of ice. The aqueous suspension was neutralized to | pH=7 with 5N NaOH. After stirring for 15 min., the ester j was extracted from the aqueous phase with ethylacetate | CD (200 mL). The organic extract was washed with brine, j dried over magnesium sulfate, filtered and then | concentrated to approximately 15 mL. The resulting | crystalline solid was collected, washed with cold ethylacetate and air-dried to afford 0.7 g of the desired product, m.p. 201-204°C. N.Z. PATENT OFFICE 19 APR 1991 - 20 - 22 5 9 2 4 Example 18 2-f1.1'-biphenvl1-4-vl-3-(1-oxobutoxv)- -4-cruinolinecarboxylic acid A suspension of 3.0 g of 3-hydroxy-2-(l,11-bip henyl)-4—quinolinecarboxylic acid in 15 mL of butyric anhydride was treated with 6 drops of sulfuric acid. The mixture was stirred (over-head) and heated at 100°C. (steam-bath) for 3 hours. The reaction mixture was cooled and resulting crystalline solid was collected, washed with cold ethylacetate and air-dried to afford 2.0 g of the de sired product, m.p. 195-196°C. Example 19 3-Hvdroxv-6-methvl-2-f1.1»-biphenvl1-4-vl-4-auinolinecarboxylic acid A mixture of 30 g of 5-methyl-2,3-indolinedione in 200 ml of water and 30.6 g of sodium hydroxide in 100 ml of water was reacted with a solution of 47.4 g of acetoxyacetylbiphenyl in 500 ml of ethanol. The mixture was refluxed for 3 hours, then 250 ml of ethanol was removed by distillation. A 500 ml portion of water was added, the mixture was stirred, cooled to room temperature and filtered through diatomaceous earth. The filtrate was acidified with 60 ml of concentrated hydrochloric acid and 20 ml of glacial acetic acid. The resulting solid was collected, taken up in dilute ammonia and the insoluble portion collected. This solid was dissolved in 7.4N ammonia, filtered and precipitated with glacial acetic acid, giving 32.0 g of the desired product, mp 236-238°C. Example 20 6.8-Dichloro-3-hvdroxv-2-r1.11-biphenvl1-4-vl-4-cruinolinecarboxylic acid A suspension of 21 g of 5,7-dichloro-2,3-indolinedione in 120 ml of water was treated with a sufficient amount of a solution of 16.6 g of sodium hydroxide in 55 ml of water to provide solution. A warm solution of 25.4 g of acetoxyacetylbiphenyl in 350 ml of ethanol was added, followed by the balance of the alkali solution. The mixture was refluxed for 2.5 hours. During the last 1/2 21 - 22 5 9 2 4 hour 50 ml of ethanol was distilled off. A 300 ml portion of water was added, the mixture was stirred, cooled and filtered through diatomaceous earth. The solid was taken up in 1500 ml of water containing 100 ml of 10N sodium hydroxide, filtered and the filtrate treated with 32 ml of concentrated hydrochloric acid and 10 ml of glacial acetic acid. The resulting solid was dissolved in 400 ml of hot cellosolve, filtered and precipitated with water, giving 18.5 g of the desired product, mp 215-217°c. Example 21 3-Hvdroxv-8-methvl-2-ri.1'-biphenvl!-4-vl-4-cmnoUnegqgfrQWiUp acid A suspension of 16.1 g of 7-methyl-2,3-indoline-dione in 120 ml of water was treated with a sufficient amount of a solution of 16.6 g of sodium hydroxide in 55 ml of water to provide solution. A warm solution of 25.4 g of acetoxyacetylbiphenyl in 350 ml of ethanol was added, followed by the balance of the alkali solution. The mixture was refluxed for 2.5 hours. During the last 1/2 hour 50 ml of ethanol was distilled off. A 300 ml portion of water was added, the mixture was stirred, cooled and filtered through diatomaceous earth. The filtrate was treated with 34 ml of concentrated hydrochloric acid and 12 ml of glacial acetic acid. The resulting solid was collected and recrystallized from ethanol/water, giving 13.6 g of the desired product, mp 178-180°C. Example 22 6-Fluoro-3-hvdroxv-2-r1.11-biphenvl1-4-vl-4-cruinolinecarboxvlic acid A suspension of 6.6 g of 5-fluoro-2,3-indoline-dione in 48 ml of water was treated with a sufficient amount of a solution of 6.62 g of sodium hydroxide in 22 ml of water to provide solution. A warm solution of 10.17 g of acetoxyacetylbiphenyl in 80 ml of ethanol was added, followed by the balance of the alkali solution. The mixture was refluxed for 3 hours. During the last 1/2 hour 100 ml of ethanol was distilled off. A 103 ml portion of water was added, the mixture was stirred, - 22 ?2 5 92- cooled and filtered through diatomaceous earth. The filtrate was treated with 13.6 ml of concentrated hydrochloric acid and 4.39 ml of glacial acetic acid and stirred for 30 minutes. The resulting precipitate was 5 collected, washed with water and ether and air dried. The resulting solid was stirred and heated in 400 ml of ethanol. The solid was collected, washed with water and dried giving 11.2 g of the desired product, mp 252-254°C. Example 23 10 2-(3.4-Dichlorophenvl)-3-hvdroxv-6-methvl-4- auinolinecarboxylic acid A suspension of 16.1 g of 5-methyl-2,3-indoline-dione in 120 ml of water was treated with a sufficient amount of a solution of 16 g of sodium hydroxide in 60 ml 15 of water to provide solution. A warm solution of 24.7 g of 3', 4*-dichloro-2—hydroxyacetophenone, acetate in 250 ml of ethanol was added followed by the balance of the alkali solution. The mixture was refluxed for 3 hours and 75 ml of alcohol was distilled off. The mixture was cooled, 20 treated with 300 ml of water, stirred and filtered through diatomaceous earth. The filtrate was acidified with 33 ml of concentrated hydrochloric acid and 12 ml of glacial acetic acid, cooled for 3 hours and the resulting solid collected. This solid was dissolved in 800 ml of boiling 25 methyl cellosolve, treated with charcoal, filtered and cooled. This solid was collected, giving 10.2 g of the desired product, mp 250°C (dec.). Following the general procedures described in Examples 13-23, the compounds listed in the following 2Q Table IV as Examples 24-56 were prepared. n.z. patent office 19 APR 1991 35 I o o 0 o TABLE IV Derivative Product MP°C 4l-Chloro-2-hydroxyaceto- 2-(4-Chlorophenyl) -6-f luoro-3- 210-212 phenone, acetate hydroxy-4-quinolinecarboxylic acid Ex. 2,3-lndolinedione Acetyl 24 5-Fluoro- 25 5-Bromo- Acetoxyacetylbiphenyl 3-(Acetyloxy)-2-[1,11-biphenyl]-4- 271-275 yl-6-bromo-4-quinolinecarboxylic acid 26 5-Fluoro- 4-(21-Fluoropheny1)-phenacylacetate 6-Fluoro-2-(21-fluoro[l,l*-biphenyl ] -4 -yl ) -3 -hydroxy- 4 -quino-1inecarboxylic acid 212-214 27 5-Bromo- 4'-Chloro-2-hydroxyaceto-phenone, acetate 6-Bromo-2-(4-chlorophenyl)-3- 201-203 hydroxy-4-quinolinecarboxylic acid 28 5,7-Dichloro- CO 4-Chloro-2-hydroxyaceto-phenone, acetate 6,8-Dichloro-2-(4-chlorophenyl)-3-hydroxy-4-quinolinecarboxylic acid 214-216 t/.sJt. A'FW.v > o o TABLE IV (continued! Ex. 2,3-Indolinedione Acetyl Derivative Product MP°C 29 5-Methyl- 4-Chloro-2-hydroxyaceto- 2-(4-Chlorophenyl)-3-hydroxy-6- 247-248 phenone, acetate methyl-4-quinolinecarboxylic acid 30 5-Bromo- 4-Iodo-2-hydroxyaceto- 6-Bromo-3-hydroxy-2-(4-iodophen- 242-244 phenone, acetate yl)-4-quinolinecarboxylic acid O 31 5-Pluoro- 4-Fluoro-2-hydroxyaceto- 6-Fluoro-2-(4-fluorophenyl)-3- 220-224 phenone, acetate hydroxy-4-quinolinecarboxylic acid 32 5- Bromo- 4-(4•-Methoxypheny1)-propiophenone 6-Bromo-3-hydroxy-2-(4'-methoxy-[1,1'-biphenyl]-4-y1)-4-quinolinecarboxylic acid 245- -247 33 5- -Bromo- 4-Fluoro-2-hydroxyaceto-phenone, acetate 6-Bromo-2-(4-fluorophenyl)-3-hydroxy-4-quinolinecarboxylic acid 195- -197 34 5- ■Fluoro- 2\4'-Dif luoro-2-hydroxy-acetophenone, acetate 2-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-4-quinolinecarboxylic acid 207 -208 N.Z. PATENT OFFICE 19 APR 1991 r\> ro LTl VO ro _1L o o 0 TABLE IV (continued! Ex. 2,3-Indolinedione Acetyl Derivative Product MP°C 35 5-Bromo- 2\ 4uDifluoro-2-hydroxy-acetophenone, acetate 6-Bromo-2-(2,4-difluorophenyl)-3- 208-209 hydroxy-4-quinolinecarboxylic acid 36 5-Chloro- 4-(4i-Methoxyphenyl)-propiophenone 6-Chloro-3-hydroxy-2-(4•-methoxy- 215-218 [1,1'-biphenyl]-4-yl)-4-quinolinecarboxylic acid 37 5-Fluoro- 4-(4'-Methoxyphenyl)- 6-Fluoro-3-hydroxy-2-(41-methoxy- 253-255 propiophenone [1,1•-biphenyl]-4-yl)-4-quinoline carboxylic acid 38 5,7-Dichloro- 3', 4-Dichloro-2-hydroxy- acetophenone, acetate 6,8-Dichloro-2-(3,4-dichlorophen- 264-266 yl)-3-hydroxy-4-quinolinecarbox-ylic acid 39 5,7-Dichloro- 4-Iodo-2-hydroxyaceto- phenone, acetate 6,8-Dichloro-3-hydroxy-2-(4-iodo- 270-272 phenyl)-4-quinolinecarboxylic acid 40 5-Fluoro- 2-(Acetyloxy)-l-(4- 6-Fluoro-3-hydroxy-2-(4-phenoxy- 201-203 phenoxyphenyl)ethanone phenyl)-4-quinolinecarboxylic acid ro ro en vO ro N.Z. PATENT OFFIC6 19 APR 1991 «CHVTD 0 0 0 0 TABLE IV (continued! EX. 2,3- •Indolinedione Acetyl Derivative Product MP0 C 41 Unsubstituted 2-(Acetyloxy)-l-(4-phen-oxyphenyl)ethanone 3-Hydroxy-2-(4-phenoxypheny1)-4-quinolinecarboxylic acid 200- 201 42 5- Methyl- 2-(Acetyloxy)-1-(4-phen-oxyphenyl)ethanone 3-Hydroxy-6-methyl-2-(4-phenoxy-phenyl)-4-quinolinecarboxylic acid 197- ■198 43 5- -Bromo- 2-(Acetyloxy)-1-(4-phen-oxyphenyl) ethanone 6-Bromo-3-hydroxy-2-(4-phenoxy-phenyl)-4-quinolinecarboxylic acid 264- -267 44 5- -Fluoro- 2-(Acetyloxy)-l-[4-(phenylroethyl)phenyl 3 -ethanone 6-Fluoro-3-hydroxy-2-[4-(phenyl-methy1)phenyl]-4-qu inolinecarboxyl ic acid 194- -196 45 5- -Fluoro- 2-(Acetyloxy)-l-[4-(phenylthio)phenyl]-ethanone 6-Fluoro-3-hydroxy-2-[4-(pheny1-thio)phenyl]-4-quinolinecarboxylic acid 196- -198 46 5- -Bromo- 2-(Acetyloxy)-1-[4-(phenylthio)phenyl)-ethanone 6-Bromo-3-hydroxy-2-(4-phenyl-thio)phenyl)-4-quinolinecarboxylic acid 182' -184 NZEMtNTOFFICg 19 APR 1991 mw"? </div>

Claims

A. 0 0 0 0. TABLE IV (continued) EX. 2,3-Indolinedione Acetyl Derivative Product MP°C 47 5-Fluoro 2-(Acetyloxy-l-[4-(l, 1-dimethylethyl)phenyl]-ethanone 2-[4-(1,l-Dimethylethy1)phenyl]-6-fluoro-3-hydroxy-4-quinolinecar-boxylic acid 206-207 48 Unsubstituted 2-(Acetyloxy)-1-[4-(phenylmethyl)phenyl)-ethanone 3-Hydroxy-2-[4-(phenylmethyl)-phenyl)-4-quinolinecarboxylic acid 187-189 49 Unsubstituted 2-(Acetyloxy)-l-[4-(2,4- 2-[4-(2,4-Dichlorophenoxy)phenyl)- 201-203 dichlorophenoxy)phenyl]- 3-hydroxy-4-quinolinecarboxylic ethanone acid 50 5-Fluoro- 2-(Acetyloxy)-l-(4-(2,4-dichlorophenoxy)phenyl] • ethanone 2-[4-(2,4-Dichlorophenoxy)phenyl)- 196-199 6-fluoro-3-hydroxy-4-quinolinecar-boxylic acid 51 5-Bromo- 2-(Acetyloxy)-l-[4-(phenylmethyl)phenyl]-ethanone 6-Bromo-3-hydroxy-2-[4-(pheny1-methy1)phenyl)-4-quinolinecarboxylic acid 192-194 52 5-Bromo- N.Z. PATENT OFFICE 19 APR 1991 2-(Acetyloxy)-1-[4-(2,4- 6-Bromo-2-[4-(2,4-dichlorophen- 190-192 dichlorophenoxy)phenyl]- oxy)phenyl]-3-hydroxy-4-quinoline-ethanone carboxylic acid ro K> cn vO ro o 225924 28 - WHAT WE CLAIM IS:

1. A compound of the formula: wherein Rx is hydrogen, halogen or alkyl (C^-Cg) y R2 is hydrogen, halogen, trif luoromethyl or alkyl (^-Cg) y R^ is hydroxy or alkanoyloxy(C2-Cfi)y R4 is trifluoromethyl, halogen, hydroxy, alkyl (^-Cg) > phenyl, benzyl, phenoxy, phenylthio, cycloalkyl(C3~C6), 2,4-dichlorophenoxy or monc-or di-substituted phenyl wherein the substituents are halogen or alkoxy (C^Cg) y and Rg is hydrogen or h&logeny with the proviso that when R^ is hydrogen, R2 is other than fluoro, and R3 is hydroxy then R^ may not be chloro, bromo, iodo, methyl or phenyl.

2. The compound according to Claim 1, wherein the compound is 6-fluoro-3-hydroxy-2-[l,l'-biphenyl]-4-yl-4--quinolinecarboxylic acid, 3-(acetyloxy)-2-[1,1'-biphenyl]--4-yl-4-quinolinecarboxylic acid, or 6,8-dichloro--3-hydroxy-2-[1,1'-biphenyl]-4-quinolinecarboxylic acid.

3. The compound according to Claim 1, wherein the compound is 3-hydroxy-8-methyl-2-[l,l'-biphenyl]-4-yl-4-quin-olinecarboxylic acid, 6-fluoro-2-(2'-fluoro[l,l'-biphenyl]-3--hydroxy-4-quinolinecarboxylic acid, 6,8-dichloro-2-(3,4-di-chlorophenyl)-3-hydroxy-4-quinolinecarboxylic acid, 3-(acetyloxy) -2- [l,l'-biphenyl]-4-yl-6-bromo-4-quinolinecarboxylic acid, or 6-fluoro-3-hydroxy-2(4'-methoxy[1,1'-biphenyl]-4--yl)-4-quinolinecarboxylic acid. v. . . im nifiKMMNMttMWWinhiw w.so~ r..„ ? 2 592 4 - 29 -

4. A process for producing a compound of the formula: wherein R_t R„, R_, R. and R_ are as defined in Claim l, X 2 3 4 9 which comprises reacting a 2,3-indolinedione of the formula: wherein R^ and R2 are as hereinbefore defined in basic aqueous solution with a (C1-C2) alkanolic solution of an acetophenone of the formula: wherein R^ and R& are as hereinbefore defined and R is methyl or -O-CO-alkyl(C^-Cg) at the reflux temperature of the reaction mixture.

5. A pharmaceutical composition in unit dosage form comprising a compound of any one of Claims 1 to 3 in association with ^pHarfriacfflTJg±Gac^| acceptable carrier. ^jDATED THIS G'H-vDAYOF' k. J. P/AflKA/son lj>ER ^GENTj PPLICANTS 19